Human Fc gamma RIIA / CD32a (R167) binding Kit (TR-FRET)

• Comprehensive validation - Validated with various antibody subtypes and antibody drugs.
• Simple and fast operation - No complicated washing steps, significantly reducing time.
• High batch consistency - Strict control over raw materials and finished product quality, ensuring a stable supply.
• Accurate and reliable results - High sensitivity with minimal matrix effects.
• High throughput capability - Support multiple product specifications, ideal for high-throughput screening.
• Fast completion - Results in just 1 hour.

The Human Fc gamma RIIA / CD32a (R167) binding Kit (TR-FRET) is based on a homogeneous (no wash) competition TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer) to measure the interaction between human CD32a (R167) and antibody drug candidates or CD32a (R167) inhibitors. It is designed to facilitate the ADCC and ADCP functional performance evaluation of antibody drug candidates, high-throughput screening of CD32a (R167) inhibitors within 0.5-1 hours. It can also be used as a universal detection tool to identify the ability of antibody drugs to bind to human CD32a (R167).

1. Unopened kit should be stored at 2℃-8℃ upon receiving.

2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

Human Fc gamma RIIA / CD32a (R167) binding kit (TR-FRET) is based on TR-FRET technology (Time-Resolved Fluorescence Resonance Energy Transfer). Use the mixture of biotinylated human Fc gamma RIIA / CD32a (R167) and Europium-chelate labeled streptavidin as the donor, FA labeled Human IgG1 antibody as the acceptor.

- In the absence of human Fc gamma RIIA/CD32a (R167) binding components, the donor and acceptor are in close proximity due to the binding of human Fc gamma RIIA/CD32a (R167) and FA-labeled Human IgG1 antibody. Upon excitation with a specific light source, the donor emits a 620 nm signal, which is absorbed by the acceptor, resulting in a 665 nm emission.

- In the presence of human Fc gamma RIIA/CD32a (R167) binding components, they disrupt the donor-acceptor interaction, preventing FRET from occurring.